Patents Issued in October 12, 2023
  • PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
    Publication number: 20230322789
    Abstract: Provided in the present application are a compound represented by formula (I), a pharmaceutical composition containing the compound, and the use thereof. The compound represented by formula (I) of the present application has a good effect in terms of inhibiting the activity of HPK1.
    Type: Application
    Filed: November 3, 2021
    Publication date: October 12, 2023
    Applicant: BroadenBio Co., Ltd.
    Inventors: Gongping Duan, Xingmin Zhang, Zhihua Wang, Xianglong Wei, Min Li
  • COMPOUNDS AND THEIR METHODS OF USE
    Publication number: 20230322790
    Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.
    Type: Application
    Filed: March 10, 2023
    Publication date: October 12, 2023
    Inventors: Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
  • CDK2 INHIBITORS
    Publication number: 20230322791
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: February 8, 2023
    Publication date: October 12, 2023
    Inventors: Douglas Wilson, Neil Bifulco, JR., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • CDK9 INHIBITORS
    Publication number: 20230322792
    Abstract: or a stereoisomer or salt (e.g., pharmaceutically acceptable salt) thereof, wherein R1, R2, R3, R4, R5, p, m, and n are as defined herein. Use of the compounds as a component of a pharmaceutical compositions and methods for their use are also provided.
    Type: Application
    Filed: April 6, 2023
    Publication date: October 12, 2023
    Inventors: Hariprasad Vankayalapati, Zhaoliang Li, Kyle Medley, Kimberley Coffman, Dongqing Yan, David J. Bearss
  • 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza
    Publication number: 20230322793
    Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
    Type: Application
    Filed: February 27, 2023
    Publication date: October 12, 2023
    Applicant: Novartis AG
    Inventors: Maxime Dauphinais, Rama Jain, Dennis Christofer Koester, James R. Manning, Vanessa Marx, Daniel Poon, Lifeng Wan, Xiaojing Michael Wang, Aregahegn Yifru, Qian Zhao
  • PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
    Publication number: 20230322794
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: June 6, 2023
    Publication date: October 12, 2023
    Inventors: Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew M. Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder
  • COTTON FABRICS CONTAINING POROUS ORGANIC CAGES
    Publication number: 20230322795
    Abstract: Highly porous nucleophilic organic cages (Nu-POC) were in-situ synthesized on cotton fibers by a condensation reaction between cyanuric chloride and melamine, and the products were employed as a robust wearable and flexible detoxifying protective material (denoted as POCotton) for vaporous pesticides. The covalent growth of Nu-POC particles on surfaces of cotton fibers retained the physical characteristics of Nu-POC to the greatest extend, which include specific surface area and porosity, while the cotton fabrics still remained wearable. The resultant POCotton can repeatedly adsorb fumigant vapors instantly (i.e., equilibrium reached within one minute) and massively (i.e., adsorption capacity at 596.88 mg/g of methyl iodide).
    Type: Application
    Filed: October 22, 2021
    Publication date: October 12, 2023
    Inventors: Gang SUN, Peixin TANG
  • PROCESS FOR THE PREPARATION OF 2,2-DIFLUORO-1,3-BENZODIOXOLE DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS
    Publication number: 20230322796
    Abstract: A process for the preparation of compound of formula (I) is provided, re) wherein X, R1 and R2 are as defined in the claim 1.
    Type: Application
    Filed: August 26, 2021
    Publication date: October 12, 2023
    Applicant: SYNGENTA CROP PROTECTION AG
    Inventor: Michel MUEHLEBACH
  • SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS
    Publication number: 20230322797
    Abstract: Provided herein are solid forms comprising a compound of formula (I), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of synthesizing a compound of formula (I), pharmaceutical compositions comprising the same, and methods of treating, preventing, and managing various disorders using the compositions provided herein.
    Type: Application
    Filed: April 6, 2023
    Publication date: October 12, 2023
    Inventors: Christopher G. F. COOPER, Baudouin GERARD, Joshua Courtney HORAN, Jason T. KROPP, Benjamin Stephen LANE, David James PEARSON, Lauren Ashley MACEACHERN, Yameng HE, Mandeep SINGH, Arkesh NARAYANAPPA
  • ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4
    Publication number: 20230322799
    Abstract: Disclosed herein are 1,2,3,4-tetrahydroisoquinolines and 4, 5, 6, 7-tetrahydrothieno [2, 3-cjpyridines, useful as antagonists of the muscarinic acetylcholine receptor M4 (mA·Ch·RM4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
    Type: Application
    Filed: August 13, 2021
    Publication date: October 12, 2023
    Inventors: Aaron M. Bender, Matthew Spock, P. Jeffrey Conn, Craig W. Lindsley
  • LIGHT EMITTING DEVICE AND FUSED POLYCYCLIC COMPOUND FOR THE LIGHT EMITTING DEVICE
    Publication number: 20230322802
    Abstract: A light emitting device includes a first electrode, a second electrode facing the first electrode, and an emission layer disposed between the first electrode and the second electrode, wherein the emission layer includes a first compound represented by Formula 1 below:
    Type: Application
    Filed: February 24, 2023
    Publication date: October 12, 2023
    Inventors: Kyoung SUNWOO, TAEIL KIM, JUNHA PARK, MinJae SUNG, MUN-KI SIM, MINJUNG JUNG
  • SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER
    Publication number: 20230322803
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein Ring A is a carbon-linked ring; and Ring A, R1, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: March 22, 2021
    Publication date: October 12, 2023
    Inventors: Andrew P. Degnan, Godwin Kwame Kumi, Andrew J. Tebben, Audris Huang, Peter Kinam Park, Donna M. Bilder, Emily Charlotte Cherney, Ashok Vinayak Purandare
  • REAGENTS FOR REVERSIBLY PROTECTING BIOLOGICAL MOLECULES
    Publication number: 20230322804
    Abstract: The present invention concerns reagents for the reversible protection of biological molecules. It relates in particular to compounds derived from azaisatoic anhydride and their uses for the protection of biological molecules, particularly enzymes, in order to block their activity. The invention also relates to the biological molecules protected in this manner and to the methods for making use of these reagents.
    Type: Application
    Filed: June 2, 2023
    Publication date: October 12, 2023
    Applicants: BIOMÉRIEUX, UNIVERSITÉ DE CAEN NORMANDIE
    Inventors: Sylvain URSUEGUI, Alain LAURENT, Ali LAAYOUN, Frédéric FABIS
  • NOVEL PYRIMIDODIAZEPINE DERIVATIVES OR USES THEREOF
    Publication number: 20230322805
    Abstract: The present invention relates to a pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof and a use thereof. A pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof according to the present invention can bind specifically to DNAJC3 and PDIA3, which are inhibitory of PERK signaling activation, to prevent the inhibition against PERK signaling. Thus, having an advantage of effectively suppressing or inhibiting tau aggregation, the pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof can not only be used in a pharmaceutical composition capable of fundamentally preventing or treating tauopathies associated with the activation of tau protein, but also can find applications in various studies on the development of therapeutic agents for tauopathies, and the expression or activity inhibition of tau protein.
    Type: Application
    Filed: August 31, 2021
    Publication date: October 12, 2023
    Inventors: Seung Bum PARK, Young Hee SHIN
  • MACROCYCLES FOR USE IN TREATING DISEASE
    Publication number: 20230322806
    Abstract: The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.
    Type: Application
    Filed: March 17, 2023
    Publication date: October 12, 2023
    Inventors: Evan W. Rogers, Jane Ung, Vivian Nguyen, Dayong Zhai, Wei Deng, Jingrong J. Cui
  • Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom
    Publication number: 20230322807
    Abstract: Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.
    Type: Application
    Filed: May 19, 2023
    Publication date: October 12, 2023
    Inventors: Jan Vågberg, Styrbjörn Byström
  • CRYSTALLINE FORM OF HETEROBICYCLIC COMPOUND
    Publication number: 20230322812
    Abstract: An object of the present invention is to provide a crystal of compound 1, which is useful as an antitumor agent, the crystal being stable, excellent in oral absorbability, highly chemically pure, and suitable for mass production. The present invention provides a crystal of compound 1 that exhibits an X-ray powder diffraction spectrum containing, at diffraction angles 2?±0.2°, characteristic peaks of at least 3 characteristic peaks selected from the group consisting of 5.8°, 9.8°, 12.2°, 14.0°, 15.3°, 21.1°, and 27.6°.
    Type: Application
    Filed: August 24, 2021
    Publication date: October 12, 2023
    Applicants: TAIHO PHARMACEUTICAL CO., LTD., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Takashi MITA, Daisuke TAKEDA
  • COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS
    Publication number: 20230322813
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Application
    Filed: March 1, 2023
    Publication date: October 12, 2023
    Inventors: Byoung-Kwon Chun, Rao V. Kalla, Richard L. Mackman
  • NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF
    Publication number: 20230322815
    Abstract: The present invention relates to compounds of Formula I: wherein R1, L1, A, Xa, L2, B and Xb are each as defined herein. The present invention also relates to compounds of Formula II and III defined herein, formed by self-assembly of the compounds of Formula I with a metal M and an anion Q. Compounds of Formula II and III are useful in the treatment of proliferative disorders, such as cancer. The present invention also relates to pharmaceutical compositions comprising compounds of Formula I, II or III, and to the use of these compounds and compositions in the treatment of proliferative disorders, such as cancer.
    Type: Application
    Filed: August 10, 2021
    Publication date: October 12, 2023
    Inventors: Simon John Allison, Roger Mortimer Phillips, Craig Raymond Rice
  • PYRAZOLE BORONIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES THEREOF
    Publication number: 20230322816
    Abstract: The present application relates to a pyrazole boronic acid compound represented by the following formula I, pharmaceutically acceptable salts or stereoisomers thereof, a pharmaceutical composition containing same, and uses thereof. The compound, the pharmaceutically acceptable salts or stereoisomers thereof and the pharmaceutical composition containing same can be used for preparing proteasome inhibitors.
    Type: Application
    Filed: August 19, 2021
    Publication date: October 12, 2023
    Inventors: Runtao Li, Yuanqiang Wang, Liqiang Han, Zhuanzhuan Song, Zemei Ge, Xin Wang
  • SILICON COMPOUND, REACTIVE MATERIAL, RESIN COMPOSITION, PHOTOSENSITIVE RESIN COMPOSITION, CURED FILM, METHOD OF MANUFACTURING CURED FILM, PATTERNED CURED FILM, AND METHOD OF MANUFACTURING PATTERNED CURED FILM
    Publication number: 20230322818
    Abstract: There is provided a silicon compound represented by General Formula (x). There is also provided a reactive material containing a silicon compound represented by General Formula (x).
    Type: Application
    Filed: October 21, 2020
    Publication date: October 12, 2023
    Inventors: Takashi MASUBUCHI, Yuri OIKAWA, Kazuhiro YAMANAKA
  • BISACYL DIGERMANIUM COMPOUNDS, THEIR PREPARATION AND THEIR USE AS PHOTOINITIATOR FOR RADICAL POLYMERIZATION
    Publication number: 20230322820
    Abstract: The present invention discloses photoinitiators according to the general formula R1R2R3—Ge—Ge—R4R5R6, wherein each R1 and R4 is an acyl group, and the use of such photoinitiators for radical polymerization.
    Type: Application
    Filed: April 1, 2023
    Publication date: October 12, 2023
    Inventors: Michael HAAS, Tanja WIESNER
  • QUINOLINONE DERIVATIVE COMPOUND SELECTIVELY BINDING TO CYSTEINE, PEPTIDE CONJUGATE THEREOF, AND ANTIBODY-DRUG CONJUGATE COMPRISING SAME
    Publication number: 20230322821
    Abstract: The present disclosure relates to a quinolinone derivative compound selectively binding to cysteine, an amino acid- or peptide-conjugate thereof, and an antibody-drug conjugate comprising same. Since a conjugate with high chemoselectivity and high yield is formed through a radical pathway induced by visible light, the present disclosure can be applied in various ways to bioconjugation.
    Type: Application
    Filed: August 25, 2021
    Publication date: October 12, 2023
    Inventors: Sungwoo HONG, Jaebong JANG, Hangyeol CHOI, Myojeong KIM
  • ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF
    Publication number: 20230322822
    Abstract: The present invention provides aryl phosphorous oxide compounds with kinase inhibitory activity. The compounds are capable of effectively inhibiting activity of various types of EGFR drug-resistant mutants (such as EGFRdel19, EGFRdel19/T790M, EGFRdel19/C797S, EGFRT790M/L858R, EGFRL858/C797S, EGFRdel19/T790M/C797S, and EGFRL858R/T790M/C797S, and also have significant inhibitory effect on ALK fusion genes and mutants (such as L1196M), and are capable of being used for the treatment, combined treatment or prevention of various types of cancers.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 12, 2023
    Applicant: Chengdu Di'ao Jiuhong Pharmaceutical Factory
    Inventors: Peng He, Guangxin Dong, Hai Zhao, Xuechao Wang, Shuang Chen, Pei Huang, Ta Deng, Ru Zhang, Haiyan LI
  • PROMOIETY STRATEGY TO ENHANCE DRUG ACTIVITY
    Publication number: 20230322823
    Abstract: Various nucleoside phosphate and phosphonate analogues are provided for treatment of viral infections. Methods of preparing the analogues, pharmaceutical compositions containing the analogues, and methods of using the analogues as antiviral compounds, especially against adenoviruses, coronaviruses, and varicella zoster viruses, are also provided.
    Type: Application
    Filed: August 18, 2021
    Publication date: October 12, 2023
    Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventor: Charles E. MCKENNA
  • METAL COMPLEXES
    Publication number: 20230322826
    Abstract: The present invention relates to metal complexes and to electronic devices, in particular organic electroluminescent devices, containing these metal complexes.
    Type: Application
    Filed: June 1, 2023
    Publication date: October 12, 2023
    Inventors: Philipp STOESSEL, Christian EHRENREICH
  • ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING ORGANOMETALLIC COMPOUND
    Publication number: 20230322827
    Abstract: An organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound: wherein, in Formula 1, Y2, a ring CY2, R1 to R8, R20, A1 to A7 and d2 may be each independently the same as described in the specification.
    Type: Application
    Filed: June 15, 2023
    Publication date: October 12, 2023
    Inventors: Yongsuk CHO, Soyeon KIM, Jiyoun LEE, Jongwon CHOI, Dmitry Kravchuk, Banglin LEE, Ohyun KWON, Kyuhyun IM
  • ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE
    Publication number: 20230322828
    Abstract: An organometallic compound represented by Formula 1: M1(L1)n1(L2)n2??Formula 1 wherein, M1 is a transition metal, L1 is a ligand represented by Formula 1A, L2 is a ligand represented by Formula 1B, n1 and n2 are each independently 1 or 2, Formula 1A Formula 1B wherein X1 to X4 are each independently C or N, rings CY1 and ring CY2 are each independently a C5-C30 carbocyclic group or a C1-C30 heterocyclic group, Z1 and Z2 are each independently Si(Q1)(Q2)(Q3) or —Ge(Q1)(Q2)(Q3), provided that each of Z1 and Z2 is not —SiH3, a1 and a2 are each independently an integer from 0 to 10, a sum of a1 and a2 is 1 or greater, Y1 and Y2 are each independently O, S, Se, or C(R5)(R6), * and *? each indicates a binding site to M1, and R1 to R3, R5, R6, and R41 to R48 are as described herein.
    Type: Application
    Filed: April 11, 2023
    Publication date: October 12, 2023
    Inventors: Bumwoo Park, Ohyun Kwon, Virendra Kumar RAI, Juhee Moon, Yong Joo Lee, Byoungki Choi, Yasushi KOISHIKAWA
  • ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
    Publication number: 20230322829
    Abstract: Cyclometalated iridium complexes having triphenylene or aza triphenylene and bulky alkyl substitution that can be used as emitters in OLEDs to improve the external quantum efficiency (EQE) and lifetime of OLEDs are disclosed.
    Type: Application
    Filed: June 2, 2023
    Publication date: October 12, 2023
    Applicant: UNIVERSAL DISPLAY CORPORATION
    Inventors: Zhiqiang JI, Alexey Borisovich DYATKIN, Jui-Yi TSAI, Pierre-Luc T. BOUDREAULT
  • Novel ruthenium complexes, methods of their preparation and application thereof in olefin cross metathesis
    Publication number: 20230322830
    Abstract: Novel ruthenium complexes of general formula 4 in which the substituents are defined herein. The present disclosure relates also to methods for preparing such compounds and use thereof as catalysts and/or (pre)catalysts in olefin cross metathesis.
    Type: Application
    Filed: August 17, 2021
    Publication date: October 12, 2023
    Applicant: Apeiron Synthesis S.A.
    Inventors: Rafal GAWIN, Andrzej Jan TRACZ, Patryk KRAJCZY
  • LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND
    Publication number: 20230322831
    Abstract: Provided is a light-emitting device including an organometallic compound represented by Formula 1-1 or 1-2, an electronic apparatus including the light-emitting device, and the organometallic compound represented by Formula 1-1 or 1-2, wherein Formulae 1-1 and 1-2 are respectively the same as those described in the present specification.
    Type: Application
    Filed: November 2, 2022
    Publication date: October 12, 2023
    Inventors: Mina Jeon, Iljoon Kang, Sungbum Kim, Sujin Shin, Eunyoung Lee, Jinhee Ju
  • METAL-ASSISTED DELAYED FLUORESCENT EMITTERS EMPLOYING PYRIDO-PYRROLO-ACRIDINE AND ANALOGUES
    Publication number: 20230322833
    Abstract: Metal-assisted delayed fluorescent (MADF) emitters including cyclic tetradentate platinum (II) and palladium (II) complexes employing 8H-pyrido[3?,2?:4,5]-pyrrolo[3,2,1-de]acridine and its analogues. These complexes provide improved color purity and enhanced operational stability and are suitable for luminescent labels, emitters for organic light emitting diodes (OLEDs), and lighting applications.
    Type: Application
    Filed: June 12, 2023
    Publication date: October 12, 2023
    Inventors: Jian Li, Yunlong Ji, JR.
  • POLYMERIZATION AND FUNCTIONALIZATION OF LEVOGLUCOSAN DERIVATIVES
    Publication number: 20230322834
    Abstract: Provided herein are polymers derived from levoglucosan, methods of preparing said polymers, and methods of modifying said polymers.
    Type: Application
    Filed: April 6, 2023
    Publication date: October 12, 2023
    Inventors: Theresa M. Reineke, Christopher J. Ellison, Mayuri Kiran Porwal, Derek J. Saxon
  • DEVICE AND METHOD FOR PREPARING SUCROSE-6-ESTER
    Publication number: 20230322836
    Abstract: Disclosed are a device and a method for preparing a sucrose-6-ester. The device includes a tank body, a heating pipe, an annular cooling apparatus, and a motor, wherein the annular cooling device and the heating pipe are arranged in the tank body in nested manner; the annular cooling apparatus includes a condensation inner wall, a condenser pipe, and a condensation outer wall that are arranged in nested manner; a distillation chamber is formed between the heating pipe and the tank body, a condensation chamber is formed between the heating pipe and the condensation outer wall, and a hollow portion of the condensation inner wall forms a reaction chamber; the heating pipe and the condensation inner wall are drove by the motor to rotate; the heating pipe is provided with a vapor outlet; an evaporation residue channel is formed at an end of the heating pipe away from the feed inlet.
    Type: Application
    Filed: February 19, 2021
    Publication date: October 12, 2023
    Inventors: Jiaxin XIA, Jingang ZHAO, Zhengsong ZHANG, Zhenghua LI, Congyong ZHANG, Xuelian ZHENG
  • PREPARATION METHOD FOR AND APPLICATION OF CLASS OF STELLATE BIFUNCTIONAL COMPOUNDS TARGETING SPIKE PROTEIN AGAINST RESPIRATORY TRACT INFECTION VIRUS AND SALT THEREOF
    Publication number: 20230322837
    Abstract: Provided are stellate compounds that target spike proteins and have a significant anti-SARS-CoV-2 ability and a certain broad spectrum. Such molecules and salts thereof have at least one basic unit R(X)n, which binds at an orthotopic binding site such as an MD domain or an allosteric site, to a virus containing spike proteins or a virus having spike proteins on its surface, thereby preventing coronavirus or other viruses which express spike proteins on their surfaces from invading host cells, and preventing the occurrence of viral infection. In addition, interaction of the molecules and salts thereof with vitamin K-dependent proteins in the human body inhibits the expression of vitamin K so as to inhibit blood coagulation in the human body, thereby treating thrombosis caused by coronavirus and producing a curative effect for pneumonia caused by a severe viral infection.
    Type: Application
    Filed: May 24, 2023
    Publication date: October 12, 2023
    Applicant: SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD.
    Inventors: Jun XU, Mengjiao HAO, Yuting ZHANG, Hao CHEN
  • DIOSMIN PREPARATION METHOD
    Publication number: 20230322838
    Abstract: Process for the preparation of diosmin.
    Type: Application
    Filed: July 8, 2021
    Publication date: October 12, 2023
    Inventors: Bruno SCHIAVI, Philppe BESCOND, Patrick MOUCHET
  • AROMATIC GLYCOSIDE AND METHOD FOR PRODUCING THE GLYCOSIDE
    Publication number: 20230322839
    Abstract: To extract, from plants such as freesia, a novel useful substance which is important in the food/pharmaceutical industry and which is expected to be useful for human health. The present inventors have found that an aromatic compound glycoside, which is a novel substance, is produced in a freesia cultivar having yellow petals such as “Ishikawa f2” in the flower thereof. The inventors have further confirmed that the glycoside exhibits an antioxidant effect, a lipid metabolism-improving effect, and a diabetes-ameliorating effect.
    Type: Application
    Filed: April 5, 2023
    Publication date: October 12, 2023
    Applicant: CAROTENOID-PRODUCTION TECHNOLOGY CORPORATION (CaroProTech)
    Inventors: Kazutoshi SHINDO, Norihiko MISAWA
  • BRIDGED NUCLEOSIDE AND NUCLEOTIDE
    Publication number: 20230322840
    Abstract: [Problem] Provision of bridged nucleosides and nucleotides that are less susceptible to decomposition by nuclease in vivo, have high binding affinity and specificity for the target mRNA, and can efficiently regulate the expression of specific genes. [Solving Means] A compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof: in the formula (I), Base shows a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group optionally having one or more substituents, R1 and R2 are each independently a hydrogen atom or the like, and R3 and R4 are each independently a hydrogen atom or the like.
    Type: Application
    Filed: June 4, 2021
    Publication date: October 12, 2023
    Inventor: Yoshiyuki Hari
  • COMPOSITION CONTAINING NUCLEIC ACID OLIGOMER
    Publication number: 20230322842
    Abstract: The purpose of the present invention is to provide a stable composition comprising a nucleic acid oligomer having a phosphorothioate bond, and a process for preparing the same composition, and a process for preparing the nucleic acid oligomer efficiently from the composition. The present invention provides a composition comprising a nucleic acid oligomer having a phosphorothioate bond represented by formula (1) (wherein the symbols are defined in the specification), an alkylammonium salt, a water-soluble organic solvent, water, and an additive including at least one compound described in the specification. The present invention provides also a modified nucleic acid oligomer.
    Type: Application
    Filed: October 20, 2022
    Publication date: October 12, 2023
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Yuya MORIYAMA, Kei ITO
  • Process for the preparation of oligonucleotides using modified oxidation protocol
    Publication number: 20230322843
    Abstract: The invention relates to a process for the production of a mixed P?O/P?S backbone oligonucleotide comprising a selective oxidation of an intermediary phosphite triester compound of formula I into a phosphodiester compound of formula II according to the scheme applying a novel oxidation protocol and to new oxidation solutions.
    Type: Application
    Filed: January 5, 2023
    Publication date: October 12, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Alec FETTES, Achim GEISER, Leonhard JAITZ
  • PROCESS FOR PREPARING (3alpha,5alpha)-3-HYDROXY-3-METHYL-PREGNAN-20-ONE (GANAXOLONE)
    Publication number: 20230322844
    Abstract: The present invention refers to a process for preparing (3?,5?)-hydroxy-3-methyl-pregnan-20-one, a compound also known as Ganaxolone, having the formula below: (I):
    Type: Application
    Filed: September 8, 2021
    Publication date: October 12, 2023
    Inventors: Roberto Lenna, Andrea Fasana, Claudio Delfrate, Jerry David Ortiz Blacio
  • NEUROACTIVE STEROIDS AND THEIR METHODS OF USE
    Publication number: 20230322846
    Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(0)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Application
    Filed: December 5, 2019
    Publication date: October 12, 2023
    Inventors: Maria Jesus Blanco-Pillado, Francesco G. SALITURO, Marshall Lee MORNINGSTAR
  • NEUROACTIVE STEROIDS AND THEIR METHODS OF USE
    Publication number: 20230322847
    Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b) N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Application
    Filed: June 13, 2023
    Publication date: October 12, 2023
    Inventors: Maria Jesus BLANCO-PILLADO, Francesco G. SALITURO, Marshall Lee MORNINGSTAR
  • NEUROACTIVE STEROIDS AND THEIR METHODS OF USE
    Publication number: 20230322848
    Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Application
    Filed: June 13, 2023
    Publication date: October 12, 2023
    Inventors: Maria Jesus BLANCO-PILLADO, Francesco G. SALITURO, Marshall Lee MORNINGSTAR
  • NEUROACTIVE STEROIDS AND THEIR METHODS OF USE
    Publication number: 20230322849
    Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(0)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Application
    Filed: June 13, 2023
    Publication date: October 12, 2023
    Inventors: Maria Jesus BLANCO-PILLADO, Francesco G. SALITURO, Marshall Lee MORNINGSTAR
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES AND DISORDERS
    Publication number: 20230322853
    Abstract: Disclosed herein are compounds (e.g., cancer) comprising a moiety that specifically binds to oligonucleotides comprising one or more repeats of GAAA (e.g., a pyrrole/imidazole polyamide) and bromodomain inhibitor and compositions and methods thereof for use in treating proliferative diseases and disorders.
    Type: Application
    Filed: April 7, 2023
    Publication date: October 12, 2023
    Inventors: Graham Erwin, Michael P. Snyder
  • HUNTINGTIN-RELATED PEPTIDE AGENTS AND USES THEREOF
    Publication number: 20230322854
    Abstract: Presented herein are novel peptides and peptide agents for diagnosing, preventing or treating Huntingtin's Disease.
    Type: Application
    Filed: September 3, 2021
    Publication date: October 12, 2023
    Inventors: Richard W. ROBERTS, Ralf LANGEN, Jeannie CHEN, Jose Mario ISAS, Kaori NORIDOMI, Terry TAKAHASHI
  • ANTI-ALLERGIC PEPTIDE AND USE THEREOF FOR IMMUNE REGULATION AND ANTI-ALLERGY
    Publication number: 20230322855
    Abstract: The invention provides an anti-allergic peptide and a use thereof for immune regulation and anti-allergy, the anti-allergic peptide is capable of inhibiting secretion of cytokines related to allergic reactions and regulating allergic reactions, and the anti-allergic peptide comprises an amino acid sequence shown in SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4 or SEQ ID No: 5, or a homologous amino acid sequence derived from substitution, deletion, and addition of one amino acid or more than one amino acid of any of the above sequences.
    Type: Application
    Filed: December 2, 2022
    Publication date: October 12, 2023
    Inventors: Pang Kuei HSU, Yu Cheng LIN, Chih Kuo KAO, Chia Feng WU
  • COMPOSITION COMPRISING REGENTIDE-012 OR REGENTIDE-013 FOR IMPROVING SKIN CONDITION
    Publication number: 20230322856
    Abstract: The present invention relates to Regentide-012 and Regentide-013 and, more specifically, to a use of Regentide-012 and Regentide-013 for improving skin conditions. Regentide-012 and Regentide-013 according to the present invention is free of cytotoxicity and have remarkable effects of skin aging reduction, skin regeneration, skin elasticity improvement, skin wrinkle prevention, skin wrinkle reduction, and skin wound recovery and as such, can be variously utilized in the pharmaceutical, medicinal, cosmetic, and food fields.
    Type: Application
    Filed: June 8, 2021
    Publication date: October 12, 2023
    Inventors: Jae Hwan KIM, Ji Heon RHIM, Ri Ra LEE, Hye In AHN, Hae Yeong KANG, Ga Hyun KIM
  • RECOMBINANTLY ENGINEERED POLYPEPTIDES CAPABLE OF RECYCLING NONCANONICAL COFACTORS
    Publication number: 20230322857
    Abstract: Provided herein are recombinantly engineered polypeptides capable of recycling noncanonical cofactors, and uses thereof. Further provided herein, is a universal growth selection process that can be used to identify said recombinantly engineered polypeptides.
    Type: Application
    Filed: April 7, 2023
    Publication date: October 12, 2023
    Inventor: Han Li